Tesamorelin is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-01-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
== Efficiency of bond-skipping == Different 2A peptides have different peptide-bond-skipping efficiencies, with T2A and P2A being the most efficient and F2A the least efficient. Therefore, up to 50% of F2A-linked proteins can in fact be produced as a fusion protein, which might cause some unpredictable outcomes, including a gain of function. One study reported that 2A sites cause the ribosome to fall off approximately 60% of the time, and that, together with ribosome read-through of about 10% for P2A and T2A, this results in reducing expression of the downstream peptide chain by about 70%. However, the level of drop-off detected in this study varied widely depending on the exact construct used, with some constructs showing little evidence of drop-off; furthermore, within a tri-cistronic transcript it reported a higher level of ribosome drop-off after one 2A sequence than after two 2As combined, which is at odds with a linear model of translation.
=== Hacktivism === Politically motivated hacktivism involves the subversive use of computers and computer networks to promote an agenda, and can potentially extend to attacks, theft and virtual sabotage that could be seen as cyberwarfare – or mistaken for it. Hacktivists use their knowledge and software tools to gain unauthorized access to computer systems they seek to manipulate or damage not for material gain or to cause widespread destruction, but to draw attention to their cause through well-publicized disruptions of select targets. Anonymous and other hacktivist groups are often portrayed in the media as cyber-terrorists, wreaking havoc by hacking websites, posting sensitive information about their victims, and threatening further attacks if their demands are not met. However, hacktivism is more than that. Actors are politically motivated to change the world, through the use of fundamentalism. Groups like Anonymous, however, have divided opinion with their anarchic methods.
== National Guard career == Noriega graduated from Chorrillos in 1962 with a specialization in engineering. He returned to Panama and joined the Panama National Guard. Posted to Colón, he was commissioned as a second lieutenant in September 1962. His commanding officer in Colón was Omar Torrijos, then a major in the National Guard. Torrijos became a patron and mentor to Noriega. In a 1962 incident Torrijos helped Noriega avoid legal trouble after a prostitute accused Noriega of beating and raping her. Soon after, Noriega's drinking and violence obliged Torrijos to confine him to his quarters for a month. Despite Noriega's problems, Torrijos maintained their relationship, ensuring they were always in the same command; he also brought Díaz Herrera into the same unit. Díaz Herrera and Noriega became both friends and rivals for Torrijos's favor. In 1964 Noriega had been posted to the province of Chiriquí, where Torrijos and Díaz Herrera were stationed. At the time, Arnulfo Arias, a native of that province, was preparing to contest the 1968 Panamanian Presidential election. Arias was a member of the National Revolutionary Party that represented the Panameñista movement. The sitting president, Roberto Chiari, belonged to the Liberal Party, which ordered Torrijos to harass Arias's party members and weaken his election bid. Torrijos passed this task on to Noriega, whose men arrested a number of people. Several prisoners said that they had been tortured; others stated they had been raped in prison.
Gajowniczek was transferred to Auschwitz on 8 October 1940. He and Kolbe met as inmates of Auschwitz in May 1941. When a camp prisoner appeared to have escaped, SS-Hauptsturmführer Karl Fritzsch ordered that ten other prisoners be executed by starvation in reprisal. Gajowniczek (prisoner number 5659) was one of those selected at roll call. When priest Maximilian Kolbe heard Gajowniczek cry out in agony over the fate of his family, he offered himself instead, for which he was later canonized. The switch was permitted. After two weeks, Kolbe (prisoner number 16670) and the three other survivors were put to death by an injection of carbolic acid. Gajowniczek was transferred from Auschwitz to Sachsenhausen concentration camp on 25 October 1944. He was liberated there by the Allies, after spending five years, five months, and nine days in concentration camps in total. He reunited with his wife Helena, six months later in Rawa Mazowiecka. She survived the war, but their sons were killed in a Soviet bombardment of Rawa Mazowiecka in January 1945 before his release.
Sources: en.wikipedia.org
Analogous to uranocene, americium is predicted to form the organometallic compound amerocene with two cyclooctatetraene ligands, with the chemical formula (η8-C8H8)2Am. A cyclopentadienyl complex is known that is likely to be stoichiometrically AmCp3. Formation of the complexes of the type Am(n-C3H7-BTP)3, where BTP stands for 2,6-di(1,2,4-triazin-3-yl)pyridine, in solutions containing n-C3H7-BTP and Am3+ ions has been confirmed by EXAFS. Some of these BTP-type complexes selectively interact with americium and therefore are useful in its selective separation from lanthanides and another actinides.
Selegiline has been limitedly studied in large animals like horses and its dosage in these animals has not been established. In preliminary research, a dose of selegiline of 30 mg orally or intravenously in horses had no observable effects on behavior or locomotor activity. The doses of selegiline used in animals are described as extremely high relative to those used in humans (which are ~0.1 mg/kg body weight).
20 December – A study published in Optica reports the first demonstration of quantum teleportation over fibers carrying conventional telecommunications traffic. 22 December – Researchers in South Korea demonstrate a way to revert cancer cells back to normal, healthy cells, using simulations to identify "master molecular switches" involved in cell differentiation. 24 December – The Parker Solar Probe breaks the previous record set in 2018 for the closest artificial object to the Sun by 6.1 million kilometers (3.8 million miles). 27 December A new technique for lifelike facial expressions on androids is reported by Osaka University, using waveform movements to dynamically express mood states, such as "excited" or "sleepy". Carbon in outer space is shown to travel on a circumgalactic medium, resembling a series of giant conveyor belts, which can extend beyond our galaxy and up to 400,000 light-years in length.
While electronic review later indicated the serve was out, Roland Garros does not use Hawk-Eye as an official officiating tool; instead, the technology is used exclusively for television broadcasts. It is noted that the broadcast version of Hawk-Eye operates with significantly lower precision than the official Electronic Line Calling (ELC) systems installed at other tournaments, leaving open the possibility that the umpire's ruling on the clay mark was accurate. However, the overrule generated controversy. Had the call not been overturned, Zverev would have broken back. Tennis commentator Robbie Koenig and former world No. 1 Andy Roddick disagreed with the overrule. Zverev would go on to lose the fifth set, giving up his two-sets-to-one lead and finishing runner-up to Carlos Alcaraz, who collected his maiden French Open title. In Halle, Zverev reached the semifinals after collecting wins against Oscar Otte, Lorenzo Sonego, and Arthur Fils, losing to Hubert Hurkacz in straight sets. At Wimbledon, Zverev beat Roberto Carballés Baena, Marcos Giron, and Cameron Norrie before losing to Taylor Fritz in the fourth round. His third-set tiebreak with Norrie was noted as one of the longest tiebreaks of the tournament, with Zverev prevailing 17–15 after 26 minutes. Back on clay, Zverev reached the final in Hamburg, losing to Arthur Fils in three sets. At the Olympic Games in Paris, Zverev represented Team Germany as defending champion.
During the Perestroika era of the Soviet Union of the late 1980s, many descendants of the Cossacks became enthusiastic about reviving their national traditions. In 1988, the Soviet Union passed a law allowing the reestablishment of former hosts and creation of new ones. The ataman of the largest, the Almighty Don Host, was granted Marshal rank and the right to form a new host. Simultaneously, many attempts were made to increase Cossack's impact on Russian society, and throughout the 1990s many regional authorities agreed to hand over some local administration and policing duties to the Cossacks. According to the 2002 Russian Census, 140,028 people self-identified as ethnic Cossacks. Between 3.5 and 5 million people associate themselves with the Cossack identity in post-Soviet Russia and around the world.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.